Aerovate Therapeutics Company Insiders

AVTE Stock  USD 2.64  0.04  1.49%   
Aerovate Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Aerovate Therapeutics suggests that all insiders are panicking. Aerovate Therapeutics employs about 51 people. The company is managed by 12 executives with a total tenure of roughly 119 years, averaging almost 9.0 years of service per executive, having 4.25 employees per reported executive.

Aerovate Therapeutics' Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2024-06-14George A EldridgeDisposed 15000 @ 25.03View
2024-05-17Hunter GilliesDisposed 4000 @ 21.08View
2024-05-16Timothy P. NoyesDisposed 10000 @ 21.58View
2024-05-02Marinus VerwijsDisposed 1981 @ 21.02View
2024-05-01Timothy P. NoyesDisposed 11357 @ 20.34View
2024-04-17Benjamin T DakeDisposed 6853 @ 22.37View
2024-04-16Timothy P. NoyesDisposed 10000 @ 24.7View
2024-04-10George A EldridgeDisposed 7500 @ 26.85View
2024-04-09David S GrayzelDisposed 11882 @ 28.15View
2024-04-01Timothy P. NoyesDisposed 10000 @ 30View
2024-03-27Benjamin T DakeDisposed 11068 @ 27.97View
2024-03-25Benjamin T DakeDisposed 3432 @ 28.01View
2024-03-19Marinus VerwijsDisposed 5300 @ 26.08View
2024-03-13George A EldridgeDisposed 2016 @ 25.02View
2024-03-11George A EldridgeDisposed 3433 @ 25.25View
2024-03-08George A EldridgeDisposed 114 @ 25View
2024-02-23Hunter GilliesDisposed 511 @ 19.5View
2024-02-20Hunter GilliesDisposed 3489 @ 20.23View
2024-02-05Ralph NivenDisposed 4600 @ 17.45View
Monitoring Aerovate Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aerovate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.

Aerovate Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.4867) % which means that it has lost $0.4867 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8206) %, meaning that it created substantial loss on money invested by shareholders. Aerovate Therapeutics' management efficiency ratios could be used to measure how well Aerovate Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 28, 2024, Return On Tangible Assets is expected to decline to -0.62. In addition to that, Return On Capital Employed is expected to decline to -0.78. At present, Aerovate Therapeutics' Other Current Assets are projected to increase significantly based on the last few years of reporting.
The current year's Common Stock Shares Outstanding is expected to grow to about 27.3 M, whereas Net Loss is projected to grow to (19.7 M).

Aerovate Therapeutics Workforce Comparison

Aerovate Therapeutics is rated third in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 581. Aerovate Therapeutics holds roughly 51.0 in number of employees claiming about 9% of equities under Health Care industry.

Aerovate Therapeutics Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aerovate Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aerovate Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Aerovate Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-09-01
1.0
2
2
 12,961 
 12,055 
2024-06-01
0.5227
23
44
 1,143,183 
 245,366 
2024-03-01
0.6226
33
53
 740,637 
 254,064 
2023-12-01
0.3409
15
44
 71,697 
 143,353 
2023-09-01
0.4194
13
31
 71,777 
 93,554 
2023-06-01
0.48
24
50
 160,255 
 146,962 
2023-03-01
0.463
25
54
 587,467 
 375,917 
2022-12-01
0.3505
34
97
 200,715 
 376,677 
2022-09-01
0.1905
4
21
 4,500 
 367,801 
2022-06-01
10.0
10
1
 125,000 
 465,582 
2021-09-01
2.4286
17
7
 23,807,956 
 43,581,181 
2021-06-01
1.9167
23
12
 16,560,070 
 7,307,255 

Aerovate Therapeutics Notable Stakeholders

An Aerovate Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Aerovate Therapeutics often face trade-offs trying to please all of them. Aerovate Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Aerovate Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Timothy PigotVP CommercialProfile
Sanjeev KhindriExecutive DevelopmentProfile
Benjamin DakePresident, FounderProfile
Timothy MBACEO DirectorProfile
Marinus VerwijsChief OfficerProfile
Stephen YuSenior QualityProfile
BSc MDSenior DevelopmentProfile
Hunter MDChief OfficerProfile
MBA MRChief OfficerProfile
Susan FischerExecutive OperationsProfile
Donna DeaHead AffairsProfile
George EldridgeCFO TreasurerProfile

About Aerovate Therapeutics Management Performance

The success or failure of an entity such as Aerovate Therapeutics often depends on how effective the management is. Aerovate Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Aerovate management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Aerovate management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.59)(0.62)
Return On Capital Employed(0.74)(0.78)
Return On Assets(0.59)(0.62)
Return On Equity(0.69)(0.66)
Please note, the presentation of Aerovate Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Aerovate Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Aerovate Therapeutics' management manipulating its earnings.

Aerovate Therapeutics Workforce Analysis

Traditionally, organizations such as Aerovate Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Aerovate Therapeutics within its industry.

Aerovate Therapeutics Manpower Efficiency

Return on Aerovate Therapeutics Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee1.5M
Net Loss Per Executive6.3M
Working Capital Per Employee2.1M
Working Capital Per Executive8.9M

Complementary Tools for Aerovate Stock analysis

When running Aerovate Therapeutics' price analysis, check to measure Aerovate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aerovate Therapeutics is operating at the current time. Most of Aerovate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aerovate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aerovate Therapeutics' price. Additionally, you may evaluate how the addition of Aerovate Therapeutics to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Equity Valuation
Check real value of public entities based on technical and fundamental data
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Commodity Directory
Find actively traded commodities issued by global exchanges